Influenza (the flu) is a highly contagious viral respiratory illness capable of causing severe complications, particularly in vulnerable populations. Understanding transmission dynamics, clinical presentation, high-risk criteria, and immunization guidelines is essential for reducing disease burden and preventing adverse outcomes.

Transmission Dynamics & Shedding

Influenza spreads primarily via large respiratory droplets generated during coughing or sneezing. Following an incubation period averaging 2 days (range: 1 to 4 days), viral shedding duration varies significantly across host populations:

• Healthy Adults: Viral shedding begins 1 day before symptom onset and persists for approximately 5 days post-onset.
• Pediatric Patients: Contagious prior to symptom onset; shedding may extend for 10 days or longer.
• Immunocompromised Hosts: Prolonged viral shedding may persist for up to 3 weeks, requiring rigorous infection control protocols.

Clinical Presentation & Complications

Unlike upper respiratory infections (common cold), influenza typically manifests with abrupt onset. High fever, severe myalgia, headache, malaise, nonproductive cough, sore throat, and rhinitis predominate. Systemic symptoms generally resolve within a week, though fatigue and cough may persist for ≥2 weeks.

Special Populations & Systemic Manifestations

• Pediatric Presentation: Frequently accompanied by acute otitis media, nausea, vomiting, and abdominal pain.
• Neurological Complications: Encephalopathy and transverse myelitis.
• Musculoskeletal & Cardiovascular: Severe myositis, myocarditis, and pericarditis.
• Pediatric Toxicity Concern: Risk of Reye syndrome associated with aspirin/salicylate administration during active viral illness.

High-Risk Populations

Vaccination Protocols & Formulations

The CDC/ACIP recommends annual influenza vaccination for all individuals aged ≥6 months without contraindications, ideally administered during early autumn. Quadrivalent formulations protect against two influenza A and two influenza B strains.

Special Administration Guidelines

• Pediatric Primer Dosing: Children 6 months through 8 years receiving their first flu vaccine require 2 doses administered ≥4 weeks apart.
• Pregnancy & Lactation: Safe in any trimester. Transplacental antibody transfer confers passive immunity to infants during their first 6 months of life.
• Egg Allergy Safety: Any age-appropriate vaccine may be administered regardless of egg allergy severity. The sole absolute contraindication is a prior severe allergic reaction to the flu vaccine itself. Observation for 15 minutes post-injection is recommended.

Antiviral Therapeutics vs. Immunization

Antiviral therapies complement—but do not replace—annual vaccination. While vaccination reduces overall infection risk, hospitalization, and mortality, targeted antivirals manage active disease or specific post-exposure clinical scenarios:

• Oseltamivir (Tamiflu): Neuraminidase inhibitor indicated for both acute treatment and post-exposure prophylaxis. Early initiation shortens symptom duration and reduces severe complications.
• Baloxavir Marboxil (Xofluza): Polymerase acidic (PA) endonuclease inhibitor approved for treating acute uncomplicated influenza in patients ≥12 years. Not indicated for post-exposure prophylaxis in this context.